Peter Hellemans
Johnson & Johnson (United States)(US)Johnson & Johnson (Brazil)(BR)
Publications by Year
Research Areas
Histone Deacetylase Inhibitors Research, Prostate Cancer Treatment and Research, Protein Degradation and Inhibitors, Chronic Lymphocytic Leukemia Research, Radiopharmaceutical Chemistry and Applications
Most-Cited Works
- → Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study(2014)251 cited
- → Prognostic value of bcl-2 expression in invasive breast cancer(1995)187 cited
- → Re: Tumor Angiogenesis as a Prognostic Assay for Invasive Ductal Breast Carcinoma(1995)157 cited
- → A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors(2013)122 cited
- → Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma(2019)115 cited
- → Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants(2015)98 cited